Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeut… Read more
Great Novel Therapeutics Biotech & Medicals (7427) - Total Liabilities
Latest total liabilities as of June 2025: NT$23.32 Million TWD
Based on the latest financial reports, Great Novel Therapeutics Biotech & Medicals (7427) has total liabilities worth NT$23.32 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Great Novel Therapeutics Biotech & Medicals - Total Liabilities Trend (2019–2024)
This chart illustrates how Great Novel Therapeutics Biotech & Medicals's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Great Novel Therapeutics Biotech & Medicals Competitors by Total Liabilities
The table below lists competitors of Great Novel Therapeutics Biotech & Medicals ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
U.S. GoldMining Inc. Common stock
NASDAQ:USGO
|
USA | $860.81K |
|
Ovostar Union N.V.
WAR:OVO
|
Poland | zł13.73 Million |
|
International Integrated Systems, Inc.
TW:6614
|
Taiwan | NT$2.12 Billion |
|
Sinkang Industries Co Ltd
TW:2032
|
Taiwan | NT$446.72 Million |
|
Valartis Group AG
SW:VLRT
|
Switzerland | CHF38.48 Million |
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
India | ₹10.95 Billion |
|
Inv Tricahue
SN:TRICAHUE
|
Chile | CL$10.97 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Great Novel Therapeutics Biotech & Medicals's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Great Novel Therapeutics Biotech & Medicals's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Great Novel Therapeutics Biotech & Medicals (2019–2024)
The table below shows the annual total liabilities of Great Novel Therapeutics Biotech & Medicals from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$29.28 Million | +9.19% |
| 2023-12-31 | NT$26.81 Million | +122.57% |
| 2022-12-31 | NT$12.05 Million | -44.24% |
| 2021-12-31 | NT$21.61 Million | +307.45% |
| 2020-12-31 | NT$5.30 Million | -71.60% |
| 2019-12-31 | NT$18.67 Million | -- |